Literature DB >> 8869796

Irinotecan (CPT-11): pharmacology and clinical applications.

N Masuda1, S Kudoh, M Fukuoka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8869796     DOI： 10.1016/1040-8428(96)00201-6

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


× No keyword cloud information.
  11 in total

1.  Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat.

Authors:  Akira Takakura; Akinobu Kurita; Takashi Asahara; Masanori Yokoba; Michiko Yamamoto; Shinichiro Ryuge; Satoshi Igawa; Yukitoshi Yasuzawa; Jiichiro Sasaki; Hirosuke Kobayashi; Noriyuki Masuda
Journal:  Oncol Lett       Date:  2011-12-09       Impact factor: 2.967

2.  Different schedules of irinotecan administration: A meta-analysis.

Authors:  Yi Shao; Hui Lv; Dian-Sheng Zhong
Journal:  Mol Clin Oncol       Date:  2016-06-03

3.  Editorial for Cancer Virtual Issue.

Authors:  Benjamin E Blass
Journal:  ACS Med Chem Lett       Date:  2017-12-14       Impact factor: 4.345

4.  DNA-PK Inhibition by NU7441 Enhances Chemosensitivity to Topoisomerase Inhibitor in Non-Small Cell Lung Carcinoma Cells by Blocking DNA Damage Repair.

Authors:  Masaaki Yanai; Haruhiko Makino; Bingqiong Ping; Kenichi Takeda; Natsumi Tanaka; Tomohiro Sakamoto; Kosuke Yamaguchi; Masahiro Kodani; Akira Yamasaki; Tadashi Igishi; Eiji Shimizu
Journal:  Yonago Acta Med       Date:  2017-03-09       Impact factor: 1.641

5.  Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

Authors:  Tracy T Batchelor; Mark R Gilbert; Jeffrey G Supko; Kathryn A Carson; Louis B Nabors; Stuart A Grossman; Glenn J Lesser; Tom Mikkelsen; Surasak Phuphanich
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

Review 6.  Cancer therapies utilizing the camptothecins: a review of the in vivo literature.

Authors:  Vincent J Venditto; Eric E Simanek
Journal:  Mol Pharm       Date:  2010-04-05       Impact factor: 4.939

7.  Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer.

Authors:  Y S Hong; H R Lee; S Park; S C Lee; I G Hwang; B-B Park; J Lee; J S Ahn; M-J Ahn; H Y Lim; K Park
Journal:  Br J Cancer       Date:  2006-11-28       Impact factor: 7.640

8.  Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer.

Authors:  A Kinoshita; M Fukuda; H Soda; S Nagashima; M Fukuda; H Takatani; M Kuba; Y Nakamura; J Tsurutani; S Kohno; M Oka
Journal:  Br J Cancer       Date:  2006-05-08       Impact factor: 7.640

9.  Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan.

Authors:  Shinichiro Ryuge; Shi-Xu Jiang; Mayuko Wada; Ken Katono; Maiko Iwasaki; Akira Takakura; Sakiko Otani; Yuka Kimura; Tomoya Fukui; Masanori Yokoba; Masaru Kubota; Masato Katagiri; Kazusige Hayakawa; Noriyuki Masuda
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

10.  A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.

Authors:  N E Schoemaker; I E L M Kuppens; V Moiseyenko; B Glimelius; M Kjaer; H Starkhammer; D J Richel; R Smaaland; K Bertelsen; J P Poulsen; E Voznyi; J Norum; D Fennelly; K M Tveit; A Garin; G Gruia; A Mourier; D Sibaud; P Lefebvre; J H Beijnen; J H M Schellens; W W ten Bokkel Huinink
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.